Ezetimibe plus statins was identified as the best regimen for preventing ischemic stroke compared to placebo (RR: 0.44, 95% CrI: 0.26-0.72; SUCRA: 0.99), followed by PCSK9 inhibitors plus statins (RR: 0.76, 95% CrI: 0.55-1.05; SUCRA: 0.56) and statins alone (RR: 0.83, 95% CrI: 0.73-0.94; SUCRA: 0.43). The gene discussed is PCSK9; the disease is ischemic stroke.